Can we rationally design promiscuous drugs?

Current Opinion in Structural Biology

Volumn 16, Issue 1, 2006, Pages 127-136

  Hopkins, Andrew L ^a   Mason, Jonathan S ^a   Overington, John P ^b  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^b Inpharmatica   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CHOLINESTERASE INHIBITOR; CYTOCHROME P450 3A4; DARUNAVIR; DONEPEZIL; DRUG METABOLIZING ENZYME; FLUOXETINE; GLUCOCORTICOID RECEPTOR; HYDROCORTISONE DERIVATIVE; IMATINIB; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; POTASSIUM CHANNEL HERG; PREGNANE X RECEPTOR; PROTEIN KINASE; PROTEIN KINASE INHIBITOR; PROTEINASE INHIBITOR; RIVASTIGMINE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; STEROID RECEPTOR; SUNITINIB; VIRUS ENZYME; VITAMIN D DERIVATIVE; VITAMIN D RECEPTOR; XENOBIOTIC AGENT;

CATALYSIS; CORRELATION ANALYSIS; DRUG BINDING SITE; DRUG DESIGN; DRUG DETERMINATION; DRUG EFFECT; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG RESEARCH; DRUG SAFETY; DRUG SELECTIVITY; DRUG TARGETING; DRUG TOLERABILITY; ENZYME INHIBITION; EVOLUTIONARY ADAPTATION; EXPERIMENTAL MODEL; EXPERIMENTAL MOUSE; GENETIC TRAIT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; HYDROPHOBICITY; IC 50; MICROARRAY ANALYSIS; MOLECULAR BIOLOGY; MOLECULAR RECOGNITION; MOLECULAR WEIGHT; MULTIDRUG RESISTANCE; MULTIGENE FAMILY; NONHUMAN; PHARMACOGENOMICS; PHARMACOPHORE; PHENOTYPE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; SUDDEN DEATH; THEORETICAL MODEL; TORSADE DES POINTES; WILD TYPE; X RAY CRYSTALLOGRAPHY;

CLUSTER ANALYSIS; DRUG DESIGN; LIGANDS; PHARMACEUTICAL PREPARATIONS;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2;

EID: 32344446028     PISSN: 0959440X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.sbi.2006.01.013     Document Type: Review

References (75)

1. B.R. Stockwell Chemical genetics: ligand-based discovery of gene function Nat Rev Genet 1 2000 116 125
2. B.L. Roth, D.J. Sheffler, and W.K. Kroeze Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia Nat Rev Drug Discov 3 2004 353 359 An excellent review of the benefits of polypharmacology for drug efficacy.
3. C.T. Keith, A.A. Borisy, and B.R. Stockwell Multicomponent therapeutics for networked systems Nat Rev Drug Discov 4 2005 71 78
4. S.K. Mencher, and L.G. Wang Promiscuous drugs compared to selective drugs (promiscuity can be a virtue) BMC Clin Pharmacol 5 2005 3 9
5. T. Hampton "Promiscuous" anticancer drugs that hit multiple targets may thwart resistance JAMA 292 2004 419 422
6. S. Frantz Drug discovery: playing dirty Nature 437 2005 942 943
7. B.Y. Feng, A. Shelat, T.N. Doman, R.K. Guy, and B.K. Shoichet High-throughput assays for promiscuous inhibitors Nat Chem Biol 1 2005 146 148
8. S.L. McGovern, B.T. Helfand, B. Feng, and B.K. Shoichet A specific mechanism of nonspecific inhibition J Med Chem 46 2003 4265 4272
9. J. Seidler, S.L. McGovern, T.N. Doman, and B.K. Shoichet Identification and prediction of promiscuous aggregating inhibitors among known drugs J Med Chem 46 2003 4477 4486 An influential paper describing the phenomena of 'frequent hitters' found in HTS, which often arise from a mechanism of aggregation.
10. B.P. Zambrowicz, and A.T. Sands Knockouts model the 100 best-selling drugs-will they model the next 100? Nat Rev Drug Discov 2 2003 38 51
11. A. Wagner Robustness against mutations in genetic networks of yeast Nat Genet 24 2000 355 361
12. A.L. Barabasi, and R. Albert Emergence of scaling in random networks Science 286 1999 509 512
13. M.E. Newman Properties of highly clustered networks Phys Rev E Stat Nonlin Soft Matter Phys 68 2003 026121
14. A.L. Barabasi, and Z.N. Oltvai Network biology: understanding the cell's functional organization Nat Rev Genet 5 2004 101 113
15. J.T. Hartman 4th, B. Garvik, and L. Hartwell Principles of the buffering of genetic variation Science 291 2001 1001 1004
16. W.G.J. Kaelin The concept of synthetic lethality in the context of anticancer therapy Nat Rev Cancer 5 2005 689 698
17. Z. Gu, L.M. Steinmetz, X. Gu, C. Scharfe, R.W. Davis, and W.-H. Li Role of duplicate genes in genetic robustness against null mutations Nature 421 2003 63 66
18. A.H. Tong, G. Lesage, G. Bader, H. Ding, H. Xu, X. Xin, J. Young, G. Berriz, R. Brost, and M. Chang Global mapping of yeast genetic interaction network Science 303 2004 808 813
19. L.E. Cowen, and S. Lindquist Hsp90 potentiates the rapid evolution of new traits: drug resistance in diverse fungi Science 309 2005 2185 2189
20. M.C. Fishman, and J.A. Porter Pharmaceuticals: a new grammar for drug discovery Nature 437 2005 491 493 An excellent synthesis of the role of pathways in drug research, the application of rare diseases for clinical proof of concept and the identification of druggable nodes within these pathways.
21. M.A. Fabian, W.H.I. Biggs III, D.K. Treiber, C.E. Atteridge, M.D. Azimioara, M.G. Benedetti, T.A. Carter, P. Ciceri, P.T. Edeen, and M. Floyd A small molecule-kinase interaction map for clinical kinase inhibitors Nat Biotechnol 23 2005 329 336
22. S. Atwell, J. Adams, J. Badger, M.D. Buchanan, I.K. Feil, K.J. Froning, X. Gao, J. Hendle, K. Keegan, and B. Leon A novel mode of Gleevec binding is revealed by the structure of spleen tyrosine kinase J Biol Chem 279 2004 55827 55832
23. C. Kung, D.M. Kenski, S.H. Dickerson, R.W. Howson, L.F. Kuyper, H.D. Madhani, and K.M. Shokat Chemical genomic profiling to identify intracellular targets of a multiplex kinase inhibitor Proc Natl Acad Sci USA 102 2005 3587 3592
24. C.M. Krejsa, D. Horvath, S.L. Rogalski, J.E. Penzotti, B. Mao, F. Barbosa, and J.C. Migeon Predicting ADME properties and side effects: The BioPrint approach Curr Opin Drug Discov Devel 6 2003 470 480 The authors describe a key biological fingerprinting approach (BioPrint) and some results of its application to predictive models of ADME and side effects.
25. W. Sneader Drug Prototypes and their Exploitation 1996 Wiley London
26. A.F. Fliri, W.T. Loging, P.F. Thadeio, and R.A. Volkmann Biological spectra analysis: linking biological activity profiles to molecular structure Proc NatlAcad Sci USA 102 2005 261 266 The analysis of biospectra/bioactivity fingerprints to link compound two-dimensional structure to biological function.
27. A.F. Fliri, W.T. Loging, P.F. Thadeio, and R.A. Volkmann Biospectra analysis: model proteome characterizations for linking molecular structure and biological response J Med Chem 48 2005 6918 6925 A discussion of the application of bioactivity fingerprints to predict biological end points, such as the efficacy and safety of a compound.
28. A.F. Fliri, W.T. Loging, P.F. Thadeio, and R.A. Volkmann Analysis of drug-induced effect patterns to link structure and side effects of medicines Nat Chem Biol 1 2005 389 397 The most recent of three key papers that describe the use of biological fingerprinting (BioPrint) data in a biospectral analysis approach to link compound structures and side effects of drugs.
29. Hopkins AL: Mapping chemical and biological space for drug discovery. In New Technologies for Drug Design and Discovery in the Post-Genome Era, July 2004, Tokyo, Japan. Chem-Biol Informatics Society of Japan: 2004.
30. M.M. Hann, A.R. Leach, and G. Harper Molecular complexity and its impact on the probability of finding leads for drug discovery J Chem Inf Comput Sci 41 2001 856 864
31. M.J. Hartshorn, C.W. Murray, A. Cleasby, M. Frederickson, I.J. Tickle, and H. Jhoti Fragment-based lead discovery using X-ray crystallography J Med Chem 48 2005 403 413 A definitive paper in the field of fragment soaking for drug discovery. It clearly brings together the multidisciplinary experimental and theoretical approaches required for the successful application of this type of lead identification approach.
32. D. Lesuisse, G. Lange, P. Deprez, D. Benard, B. Schoot, G. Delettre, J.P. Marquette, P. Broto, V. Jean-Baptiste, and P. Bichet SAR and X-ray. A new approach combining fragment-based screening and rational drug design: application to the discovery of nanomolar inhibitors of Src SH2 J Med Chem 45 2002 2379 2387
33. D.C. Rees, M. Congreve, C.W. Murray, and R. Carr Fragment-based lead discovery Nat Rev Drug Discov 3 2004 660 672
34. A.L. Hopkins, C.R. Groom, and A. Alex Ligand efficiency: a useful metric for lead selection Drug Discov Today 9 2004 430 431
35. H. Stark Turning from monogamy to strategic promiscuity Drug Discov Today 9 2004 736 737
36. F. Sams-Dodd Target-based drug discovery: is something wrong? Drug Discov Today 10 2005 139 147
37. R. Morphy, C. Kay, and Z. Rankovic From magic bullets to designed multiple ligands Drug Discov Today 9 2004 641 651
38. A.A. Borisy, P.J. Elliott, N.W. Hurst, M.S. Lee, J. Lehar, E.R. Price, G. Serbedzija, G.R. Zimmermann, M.A. Foley, B.R. Stockwell, and C.T. Keith Systematic discovery of multicomponent therapeutics Proc NatlAcad Sci USA 100 2003 7977 7982 The authors describe the application of HTS of drugs to the discovery of combination therapies.
39. R. Morphy, and Z. Rankovic Designed multiple ligands. An emerging drug discovery paradigm J Med Chem 48 2005 6523 6543 An excellent review of the various medicinal chemistry strategies for integrating separate pharmacophores into single molecules.
40. G. Kryger, I. Silman, and J.L. Sussman Three-dimensional structure of a complex of E2020 with acetylcholinesterase from Torpedo californica J Physiol (Paris) 92 1998 191 194
41. H. Kogen, N. Toda, K. Tago, S. Marumoto, K. Takami, M. Ori, N. Yamada, K. Koyama, S. Naruto, and K. Abe A conformational restriction approach to the development of dual inhibitors of acetylcholinesterase and serotonin transporter as potential agents for Alzheimer's disease Bioorg Med Chem 11 2003 4389 4415
42. A.M. Aronov, and M.A. Murcko Toward a pharmacophore for kinase frequent hitters J Med Chem 47 2004 5616 5619 A very interesting attempt to identify a promiscuous pharmacophore for protein kinases and its application in compound design.
43. Burley SK: Structure-based drug discovery for protein kinases using fragment-based lead identification/lead optimisation. In International Union of Crystallography, 20th Congress and General Assembly, 23-31 August 2005. International Union of Crystallography: Florence, Italy; 2005.
44. J. Ren, L.E. Bird, P.P. Chamberlain, G.B. Stewart-Jones, D.I. Stuart, and D.K. Stammers Structure of HIV-2 reverse transcriptase at 2.35 Å resolution and the mechanism of resistance to non-nucleoside inhibitors Proc NatlAcad Sci USA 99 2002 14410 14415
45. J. Ren, J. Diprose, J. Warren, R.M. Esnouf, L.E. Bird, S. Ikemizu, M. Slater, J. Milton, J. Balzarini, and D.I. Stuart Phenylethylthiazolylthiourea (PETT) non-nucleoside inhibitors of HIV-1 and HIV-2 reverse transcriptases. Structural and biochemical analyses J Biol Chem 275 2000 5633 5639
46. J. Auwerx, M. Stevens, A.R. Van Rompay, L.E. Bird, J. Ren, E. De Clercq, B. Oberg, D.K. Stammers, A. Karlsson, and J. Balzarini The phenylmethylthiazolylthiourea nonnucleoside reverse transcriptase (RT) inhibitor MSK-076 selects for a resistance mutation in the active site of human immunodeficiency virus type 2 RT J Virol 78 2004 7427 7437
47. A.L. Hopkins, J. Ren, J. Milton, R.J. Hazen, J.H. Chan, D.I. Stuart, and D.K. Stammers Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 1. J Med Chem 47 2004 5912 5922
48. J. Ren, C. Nichols, L. Bird, P. Chamberlain, K. Weaver, S. Short, D.I. Stuart, and D.K. Stammers Structural mechanisms of drug resistance for mutations at codons 181 and 188 in HIV-1 reverse transcriptase and the improved resilience of second generation non-nucleoside inhibitors J Mol Biol 312 2001 795 805
49. J. Ren, J. Milton, K.L. Weaver, S.A. Short, D.I. Stuart, and D.K. Stammers Structural basis for the resilience of efavirenz (DMP-266) to drug resistance mutations in HIV-1 reverse transcriptase Structure Fold Des 8 2000 1089 1094
50. J. Ren, C. Nichols, L.E. Bird, T. Fujiwara, H. Sugimoto, D.I. Stuart, and D.K. Stammers Binding of the second generation non-nucleoside inhibitor S-1153 to HIV-1 reverse transcriptase involves extensive main chain hydrogen bonding J Biol Chem 275 2000 14316 14320
51. D.L. Surleraux, H.A. de Kock, W.G. Verschueren, G.M. Pille, L.J. Maes, A. Peeters, S. Vendeville, S. De Meyer, H. Azijn, and R. Pauwels Discovery and selection of TMC114, a next generation HIV-1 protease inhibitor J Med Chem 48 2005 1965 1973
52. E. De Clercq The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection Antiviral Res 38 1998 153 179
53. M.R. Redinbo Promiscuity: what protects us, perplexes us Drug Discov Today 9 2004 431 432
54. A.M. Brown HERG block. QT liability and sudden cardiac death Novartis Found Symp 266 2005 118 131
55. A. Cavalli, E. Poluzzi, F. De Ponti, and M. Recanatini Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K(+) channel blockers J Med Chem 45 2002 3844 3853
56. G. Cianchetta, Y. Li, J. Kang, D. Rampe, A. Fravolini, G. Cruciani, and R.J. Vaz Predictive models for hERG potassium channel blockers Bioorg Med Chem Lett 15 2005 3637 3642
57. A. Aharoni, L. Gaidukov, O.McQ. Khersonsky, S. Gould, C. Roodveldt, and D.S. Tawfik The 'evolvability' of promiscuous protein functions Nat Genet 37 2005 73 76
58. A. Fernández Protein function with concurrent promiscuity J Biomol Struct Dyn 22 2005 616 617
59. D.S. Tawfik The evolvability of drug resistance: response to Fernández J Biomol Struct Dyn 22 2005 617 619
60. B. Berkhout, and R. Sanders The evolvability of drug resistance: the HIV-1 case J Biomol Struct Dyn 22 2005 615 624
61. A. Kloczkowski, T. Sen, and B. Jernigan Promiscuous vs. native protein functions. Insights from studying collective motions in proteins with elastic network models J Biomol Struct Dyn 22 2005 621 624
62. B. Berkhout HIV-1 evolution under pressure of protease inhibitors: climbing the stairs of viral fitness J Biomed Sci 6 1999 298 305
63. S.G. Dixit, R.G. Tirona, and R.B. Kim Beyond CAR and PXR Curr Drug Metab 6 2005 385 397
64. E.E. Scott, and J.R. Halpert Structures of cytochrome P450 3A4 Trends Biochem Sci 30 2005 5 7
65. J.E. Chrencik, J. Orans, L.B. Moore, Y. Xue, L. Peng, J.L. Collins, G.B. Wisely, M.H. Lambert, S.A. Kliewer, and M.R. Redinbo Structural disorder in the complex of human pregnane X receptor and the macrolide antibiotic rifampicin Mol Endocrinol 19 2005 1125 1134 A specific example of 'promiscuous pose' ligand binding to a receptor of central interest in drug discovery.
66. S.A. Jones, L.B. Moore, J.L. Shenk, G.B. Wisely, G.A. Hamilton, D.D. McKee, Tomkinson NCO, E.L. LeCluyse, M.H. Lambert, and T.M. Willson The pregnane X receptor: a promiscuous xenobiotic receptor that has diverged during evolution Mol Endocrinol 14 2000 27 39
67. K.M. Höld, N.S. Sirisoma, and J.E. Casida Detoxification of α- and β-thujones (the active ingredients of absinthe): site specificity and species differences in cytochrome P450 oxidation in vitro and in vivo Chem Res Toxicol 14 2001 589 595
68. F.J. Gonzalez Cytochrome P450 humanised mice Hum Genomics 1 2004 300 306
69. T.M. Willson, P.J. Brown, D.D. Sternbach, and B.R. Henke The PPARs: from orphan receptors to drug discovery J Med Chem 43 2000 527 550
70. R.E. Watkins, G.B. Wisely, L.B. Moore, J.L. Collins, M.H. Lambert, S.P. Williams, T.M. Willson, S.A. Kliewer, and M.R. Redinbo The human nuclear xenobiotic receptor PXR: structural determinants of directed promiscuity Science 292 2001 2329 2333
71. P.A. Williams, J. Cosme, D.M. Vinkovic, A. Ward, H.C. Angove, P.J. Day, C. Vonrhein, I.J. Tickle, and H. Jhoti Crystal structures of human cytochrome P450 3A4 bound to metyrapone and progesterone Science 305 2004 683 686 A report of the analysis of functional data in light of structural insights into the single most important CYP gene family member for drug discovery.
72. P.A. Williams, J. Cosme, A. Ward, H.C. Angove, D. Matak Vinkovic, and H. Jhoti Crystal structure of human cytochrome P450 2C9 with bound warfarin Nature 424 2003 464 468 The first structure of a human CYP gene family member complexed to the cardiovascular drug warfarin.
73. T.L. Poulos, and A.J. Howard Crystal structure of metyrapone- and phenylimidazole-inhibited complexes of cytochrome Biochemistry 26 1987 8165 8174
74. G.M. Verkhivker, P.A. Rejto, D.K. Gehlhaar, and S.T. Freer Exploring the energy landscapes of molecular recognition by a genetic algorithm: analysis of the requirements for robust docking of HIV-1 protease and FKBP-12 complexes Proteins 25 1996 342 353
75. P.A. Rejto, and G.M. Verkhivker Unraveling principles of lead discovery: from unfrustrated energy landscapes to novel molecular anchors Proc NatlAcad Sci USA 93 1996 8945 8950